TYRA - NASDAQ
Tyra Biosciences, Inc.
$28.69
-5.6%Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
At a Glance
Live SnapshotTyra Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Tyra Biosciences, Inc. Balance Sheet
TYRA • NASDAQ
| Tyra Biosciences, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
77.4M | 92M | 58M | 251.2M | 302.2M | 15.2M | 108K | |
178.6M | 249.5M | 145.5M | 0.0 | 0.0 | 0.0 | 0.0 | |
256M | 341.4M | 203.5M | 251.2M | 302.2M | 15.2M | 108K | |
0.0 | 2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 1.9M | 57K | 19K | |
9.4M | 4M | 8.2M | 6.1M | 0.0 | 0.0 | 0.0 | |
265.5M | 347.5M | 211.7M | 257.3M | 304.1M | 15.3M | 127K | |
NON-CURRENT ASSETS | |||||||
6.9M | 7.7M | 8.2M | 3.5M | 2.1M | 466K | 276K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 243K | 0.0 | |
10.3M | 8.4M | 6M | 5.4M | 555K | 21K | 125K | |
17.2M | 16.1M | 14.2M | 8.9M | 2.6M | 730K | 401K | |
282.6M | 363.6M | 225.9M | 266.2M | 306.7M | 16M | 528K | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
1.2M | 590K | 4.7M | 1.1M | 599K | 664K | 327K | |
1.2M | 590K | 4.7M | 1.1M | 599K | 664K | 327K | |
0.0 | 0.0 | 5.1M | 4.4M | 2.8M | 774K | 364K | |
472K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 412K | 280K | 140K | 202K | 142K | 139K | |
16.4M | 13.6M | 5.3M | 0.0 | 0.0 | 278K | 4.3M | |
18.1M | 14.6M | 15.3M | 5.7M | 3.6M | 1.9M | 5.2M | |
NON-CURRENT LIABILITIES | |||||||
5.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 3K | 46K | 169K | 367K | 27.8M | 0.0 | |
5.3M | 5.8M | 6.3M | 2.7M | 1.3M | 27.8M | 114K | |
0.0 | 6.2M | 6.5M | 2.6M | 1.2M | 142K | 253K | |
23.4M | 20.4M | 21.6M | 8.4M | 5M | 29.6M | 5.3M | |
SHAREHOLDERS' EQUITY | |||||||
5K | 5K | 4K | 4K | 4K | 0.0 | 0.0 | |
0.0 | 593.7M | 368.7M | 353.5M | 342.1M | 439K | 0.0 | |
-371.3M | -251.3M | -164.8M | -95.7M | -40.4M | -14.1M | -4.7M | |
393K | 770K | 381K | 0.0 | 0.0 | 0.0 | 0.0 | |
630M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
259.2M | 343.2M | 204.3M | 257.8M | 301.7M | -13.6M | -4.7M | |
259.2M | 343.2M | 204.3M | 257.8M | 301.7M | -13.6M | -4.7M | |
SUMMARY | |||||||
282.6M | 363.6M | 225.9M | 266.2M | 306.7M | 16M | 528K | |
178.6M | 249.5M | 145.5M | 0.0 | 0.0 | 243K | 0.0 | |
5.8M | 6.2M | 6.5M | 2.6M | 1.2M | 142K | 253K | |
-71.6M | -85.7M | -51.5M | -248.6M | -301M | -15.1M | 145K | |
53,318,198 | 53,318,198 | 53,318,198 | 53,318,198 | 53,318,198 | 53,318,198 | 53,318,198 |
SEC Filings
TYRA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 17, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 01, 2025 | November 25, 2025 | 2025 |
Related Guides
Continue your TYRA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.